Meeting
2024 ASCO Breakthrough
Avelumab plus axitinib for first-line treatment of advanced renal cell carcinoma: A real-world ambispective RAVE-Renal study.
Authors
Viacheslav Chubenko
St. Petersburg Clinical and Research Center of Specialized Types of Oncological Medical Care, St. Petersburg, Russian Federation
Viacheslav Chubenko , Olga Baklanova , Alexey Kalpinskiy , Sufiia Safina , Andrey Lebedinets , Alexey Shkurat , Elvira Parsadanova , Maria Turganova , Vladislav Petkau , Natalya Tovbik , Elena Tkacheva , Yulia Anzhiganova , Olga Novikova , Varvara Bragina , Ruslan Zukov , Ilya Tsimafeyeu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies
Sub Track
Real-World Evidence/Real-World Data
Clinical Trial Registration Number
KCRB01012022
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 117)
DOI
10.1200/JCO.2024.42.23_suppl.117
Abstract #
117
Poster Bd #
H7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Uptake and efficacy of immuno-oncology combinations in metastatic renal cell carcinoma in the United States: Evidence from the ASCO CancerLinQ Discovery database.
First Author: Joseph Vento
Poster
2022 ASCO Annual Meeting
Safety and efficacy of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): The results from a phase II single-arm trial.
First Author: Dawei Chen
Poster
2022 ASCO Genitourinary Cancers Symposium
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
First Author: Matthew Scott Ernst
Poster
2021 Genitourinary Cancers Symposium
Axitinib and avelumab (AA) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in the Northwest of England, United Kingdom.
First Author: Jennifer Allison